Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
7.17
+2.72 (61.12%)
At close: Mar 9, 2026, 4:00 PM EDT
6.77
-0.40 (-5.58%)
Pre-market: Mar 10, 2026, 4:19 AM EDT
Relmada Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Market Capitalization | 526 | 16 | 125 | 105 | 625 | 521 | |
| Market Cap Growth | 5807.89% | -87.41% | 18.63% | -83.18% | 19.93% | -6.06% | |
| Enterprise Value | 512 | -38 | 18 | -79 | 537 | 398 | |
| Last Close Price | 7.17 | 0.52 | 4.14 | 3.49 | 22.53 | 32.07 | |
| PB Ratio | 25.14 | 0.44 | 1.46 | 0.75 | 3.00 | 4.93 | |
| P/TBV Ratio | 55.55 | 0.44 | 1.46 | 0.75 | 3.00 | 4.93 | |
| Net Debt / Equity Ratio | -1.47 | -1.26 | -1.13 | -1.06 | -1.02 | -1.11 | |
| Net Debt / EBITDA Ratio | - | - | - | 0.92 | 1.69 | 1.97 | |
| Net Debt / FCF Ratio | 0.35 | 0.87 | 1.87 | 1.43 | 2.31 | 4.21 | |
| Quick Ratio | 2.68 | 4.36 | 7.90 | 11.94 | 14.08 | 9.30 | |
| Current Ratio | 2.86 | 4.45 | 8.00 | 12.26 | 14.83 | 9.37 | |
| Return on Equity (ROE) | -196.79% | -132.33% | -87.51% | -90.07% | -80.14% | -53.74% | |
| Return on Assets (ROA) | -102.41% | -73.14% | -51.76% | -53.57% | -46.01% | -31.52% | |
| Return on Capital Employed (ROCE) | -597.10% | -236.10% | -121.50% | -114.80% | -60.40% | -56.20% | |
| Earnings Yield | -10.68% | -509.73% | -79.28% | -149.50% | -20.13% | -11.42% | |
| FCF Yield | -7.61% | -329.85% | -41.46% | -98.81% | -14.71% | -5.34% | |
| Buyback Yield / Dilution | -5.32% | -0.21% | -1.59% | -68.80% | -12.56% | -68.97% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.